Lupin to watch for after US Approval for a generic drug
Lupin rose today a bit after the company got tentative approval from the US Food & Drug Administration for Memantine hydrochloride tablets in multiple strengths. Lupin is engaged in manufacturing active pharmaceutical ingredients and formulations. Watch for this company based on this news. The current price of Rs 1445 discounts the company’s Q2 September 2009 annualized EPS of Rs 45.66, by a PE multiple of 31.65.
*To get the password for buy calls, please subscribe to this blog. You will receive the password in next email to you*If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
Comments
No comments yet.
Leave a comment